By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Napo Pharmaceuticals, Inc. 

185 Berry Street
Suite 1300
South San Francisco  California  94080  U.S.A.
Phone: 415-371-8300 Fax: 415-371-8311



Company News
Napo Pharmaceuticals, Inc. Launches Mytesi (Crofelemer) As The Only FDA-Approved Treatment For Relief Of Noninfectious Diarrhea In HIV+ Patients 10/13/2016 7:40:10 AM
Jaguar Animal Health And Napo Pharmaceuticals, Inc. Announce Details For Proposed Merger 10/6/2016 11:52:17 AM
Napo Pharmaceuticals, Inc. And Salix (SLXP) Settle Litigation 3/7/2016 10:46:01 AM
Napo Pharmaceuticals, Inc. Files Brief On Appeal In Dispute With Salix Pharmaceuticals, Ltd. (SLXP) 2/3/2015 11:37:12 AM
Salix Pharmaceuticals, Ltd. (SLXP) Wins Napo Pharmaceuticals, Inc. Litigation 2/26/2014 6:58:39 AM
Trial Date Set for Napo Pharmaceuticals, Inc. Breach of Contract Claim Against Salix Pharmaceuticals, Ltd. (SLXP) 11/4/2013 10:04:34 AM
Napo Pharmaceuticals, Inc. Files for MUMS Designation for Crofelemer for Chemotherapy Induced Diarrhea in Dogs 9/13/2012 10:25:52 AM
The International Centre for Dispute Resolution Has Ruled in Favor of Glenmark Pharmaceuticals on the Arbitration Claim It Filed Against Napo Pharmaceuticals, Inc. 8/23/2012 10:29:03 AM
Napo Pharmaceuticals, Inc. Comments on FDA Announcing Extension of Crofelemer NDA Priority Review 5/4/2012 6:41:11 AM
Napo Pharmaceuticals, Inc. Release: New Treatment Presented for Chronic Diarrhea in HIV/AIDS Patients 3/9/2012 6:32:52 AM